Regeneron Pharmaceuticals’ (REGN) Sector Perform Rating Reiterated at Royal Bank Of Canada

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “sector perform” rating restated by research analysts at Royal Bank Of Canada in a research report issued to clients and investors on Tuesday, Benzinga reports. They presently have a $737.00 target price on the biopharmaceutical company’s stock. Royal Bank Of Canada’s target price would indicate a potential downside of 1.96% from the stock’s current price.

Other research analysts also recently issued research reports about the company. Sanford C. Bernstein upgraded Regeneron Pharmaceuticals to a “hold” rating in a research note on Wednesday, July 29th. Wells Fargo & Company lifted their price target on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an “equal weight” rating in a research note on Friday, July 31st. HSBC increased their price target on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Piper Sandler reduced their target price on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a report on Thursday, July 9th. Finally, Truist Financial increased their price objective on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Fourteen analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $802.18.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded down $0.55 during trading on Tuesday, hitting $751.70. 371,026 shares of the company’s stock traded hands, compared to its average volume of 828,012. The stock has a market capitalization of $77.40 billion, a price-to-earnings ratio of 18.58, a PEG ratio of 1.54 and a beta of 0.20. Regeneron Pharmaceuticals has a 12-month low of $541.00 and a 12-month high of $859.34. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. The business has a 50 day moving average of $781.41 and a 200-day moving average of $720.99.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping the consensus estimate of $10.16 by $4.13. The firm had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company’s revenue was up 16.7% on a year-over-year basis. During the same quarter last year, the company earned $12.81 earnings per share. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals will post 44.25 earnings per share for the current fiscal year.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Kathryn Guarini sold 400 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $340,000.00. Following the transaction, the director owned 603 shares of the company’s stock, valued at approximately $512,550. This represents a 39.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of the firm’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the transaction, the director owned 17,303 shares in the company, valued at approximately $11,249,545.45. This represents a 1.14% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 4,146 shares of company stock valued at $3,432,488. Company insiders own 6.97% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $5,682,636,000. State Street Corp boosted its position in Regeneron Pharmaceuticals by 3.6% during the 2nd quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock valued at $3,014,621,000 after acquiring an additional 170,210 shares in the last quarter. Franklin Resources Inc. boosted its position in Regeneron Pharmaceuticals by 4.4% during the 4th quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company’s stock valued at $1,975,990,000 after acquiring an additional 106,861 shares in the last quarter. Nuveen LLC increased its holdings in shares of Regeneron Pharmaceuticals by 71.1% in the 4th quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock valued at $1,551,858,000 after acquiring an additional 835,240 shares during the period. Finally, Invesco Ltd. raised its position in shares of Regeneron Pharmaceuticals by 7.2% in the 4th quarter. Invesco Ltd. now owns 1,591,105 shares of the biopharmaceutical company’s stock worth $1,228,127,000 after acquiring an additional 106,632 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Biohaven entered a clinical supply agreement to test its investigational cancer therapy BHV-1530 in combination with Regeneron’s Libtayo in solid-tumor patients. Enrollment in the combination cohort is underway, potentially supporting future Libtayo development and commercial opportunities, although the program remains early-stage. Biohaven clinical data and Libtayo agreement
• Neutral Sentiment: Royal Bank of Canada reaffirmed a “sector perform” rating and assigned a $737 price target, indicating limited near-term upside based on its published valuation view. RBC rating and price target
• Neutral Sentiment: Investors are also looking ahead to Regeneron’s third-quarter earnings report, expected October 30. Results and guidance will be important in evaluating Eylea performance, pipeline progress and the company’s valuation. Regeneron earnings outlook
• Negative Sentiment: Kodiak Sciences reported positive Phase 3 DAYBREAK data for Zenkuda and tabirafusp-tedromer in wet age-related macular degeneration. The candidates met key endpoints against Eylea while being dosed approximately every six months, compared with Eylea’s roughly eight-week schedule. If the results lead to approval and adoption, Kodiak could threaten Eylea’s market share and long-term growth. Kodiak Phase 3 eye-drug data
• Negative Sentiment: Kodiak’s shares surged after the data, highlighting investor concern that extended-dosing competitors may pressure Regeneron’s flagship ophthalmology franchise. The findings are not yet equivalent to regulatory approval, but they have increased perceived competitive risk for REGN. Kodiak competition with Eylea

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.